|
A case study of Gavi'S human papillomavirus vaccine support programme
Aimee Castro1, Margherita Cinà2, Mary Helmer-Smith3, Christian Vlček4, Collins Oghor5, Danielle Cazabon6
1 Ingram School of Nursing, McGill University, Montreal, Canada
2 Faculty of Law, McGill University, Montreal, Canada
3 Department of Biochemistry, Biostatistics and Occupational Health, McGill University, Montreal, Canada
4 School of Environment, McGill University, Montreal, Canada
5 Faculty of Medicine, McGill University, Montreal, Canada
6 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
Correspondence Address:
Danielle Cazabon
Department of Epidemiology, Biostatistics and Occupational Health, Purvis Hall, McGill University, 1020, Pine Avenue, West Montreal, QC H3A 1A2
Canada
  | Check |
DOI: 10.4103/2468-6360.198797 
|
|
Human papillomavirus (HPV), a sexually transmitted DNA virus that can lead to cervical cancer, is the most common cancer among women in developing regions. More than 270,000 women die per year from cervical cancer globally, and 85% of those deaths occur in developing countries. In the past, many low- and middle-income countries (LMICs) have been unable to afford the implementation of HPV vaccination programmes, resulting in high cervical cancer mortality rates. Gavi, an organisation created to improve worldwide access to vaccines, undertook an initiative that had the goal of decreasing the price of an HPV vaccine to under $5 and increasing access for adolescent girl populations in LMICs. This was done through market shaping, co-financing and implementation support. This case study will present and evaluate Gavi's intervention by assessing targets, investigating cost-effectiveness and identifying strategic challenges. |
